About this eBook

Drug development is high-risk, with critical decisions often made without sufficient translational insight—leading to highly costly delays and late-stage failures.

Olink protein biomarkers change this dynamic.

In Protein Biomarkers in Practice: Strategies to Reduce Drug Development Risk, discover how pharma teams use Olink high-specificity proteomics to strengthen target validation, enable earlier go/no-go decisions, and optimize patient selection across the pipeline.

Learn how Olink proteomics biomarkers have been adopted by your peers to reduce uncertainty, improve trial efficiency, and deliver actionable biological insight from every sample—providing the translational backbone to de-risk development.

Case study 1: Multiomic Integration Strengthens Causal Target Discovery in Ischemic Heart Disease

Case study 2: Improving Safety and Toxicity Biomarkers for Cancer Combination Therapies

Case study 3: Reverse Translation in Action: Using Proteomics to Decode Clinical Response to IL-6 Blockade

Case study 4: Maximizing Sample Value: Unlocking Deep Proteomic Insight from Precious Clinical Specimens

Case study 5: Early Efficacy Evaluation: Enabling Faster, Informed Go/No-Go Decisions

Case study 6: Molecular Patient Segmentation: Enriching Trials Through Proteomic Stratification

Case Study 7: Non-Invasive Endpoints: Reducing Patient Burden and Improving Recruitment in Alzheimer’s Disease